Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #92 for 7/28/2021

7/28/2021

 
​COVID-19 Vaccines
 
A 19,109 patient, British observational study described the effectiveness of COVID-19 vaccines against the Delta variant. The effectives of the Pfizer-BioNTech COVID-19 vaccine was estimated to be 88% after two doses and 67% with two doses of the AstraZeneca vaccine.
 
An analysis of data by Israeli researchers found the effectiveness of the Pfizer-BioNTech COVID-19 vaccine to be 91% to prevent severe disease and 88% to prevent hospitalizations. The vaccine had an estimated effectiveness of 41% to protect against symptomatic disease and 39% to prevent infection due to the Delta variant compared to an estimated 64% effectiveness at the beginning of July. 
 
COVID-19 Anti-Inflammatories
 
Mesoblast announced that in a 60-day, 222 patient, Phase III trial (NCT04371393), treatment with remestemcel-L added to standard of care (SOC) did not reduce all-cause mortality compared to SOC in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. In a pre-specified analysis of 123 patients under age 65, remestemcel-L reduced mortality by 46% by day 60, but not in 94 patients 65 or older. The Data Safety Monitoring Board (DSMB) recommended the trial be stopped when an interim analysis of 30-day data for 180 patients found it unlikely the trial would achieve a 43% reduction in mortality at the target enrollment of 300 patients. The DSMB recommended the trial be completed with the 222 patients already enrolled. 

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.